Generate Q1 net loss widens to $61.7M, cash $516.6M post-IPO; pipeline advances

Generate Biomedicines, Inc.

2026-Q1 EPS reported -$1.07 revenue$7,224,000

Net loss $61.7M vs $44.3M YoY; revenue $7.2M (down 18% from $8.8M).
Cash & equivalents $516.6M, includes $369.3M IPO proceeds; runway into H1 2028.
GB-0895 (anti-TSLP) Phase 3 SOLAIRIA-1/2 ongoing in severe asthma; Phase 1b in COPD.
GB-4362 (MMAE neutralizer) FDA Fast Track; first patient dosing expected mid-2026.
GB-5267 (MUC16 armored CAR T with Roswell Park) first patient expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Generate Biomedicines, Inc. reported the first quarter ended March 31, 2026 results: revenue $7.2 million, net income Net loss was $61.7 million.

Period: the first quarter ended March 31, 2026
Revenue: $7.2 million
Net income: Net loss was $61.7 million
Result: reported results

Exact text from the filing

its operations into the first half of 2028. Generate expects to require additional capital to support long-term operations. Revenue for the quarter ended March 31, 2026, was $7.2 million, compared with $8.8 million for the same period in 2025. This revenue reflects developments in the ongoing Amgen and Novartis research programs. Research and development expenses

View on SEC.gov

Browse all earnings releases →

Generate Biomedicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-209899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.